Hemispherian, an Oslo, Norway-based preclinical pharmaceutical firm, raised $2.9M within the first tranche of a Collection A funding.
The spherical was led by Meneldor, with participation from Kistefos AS, Kvantia AS, and Steven Powell.
The corporate intends to make use of the funds to assist its drug growth actions, increase its preclinical pipeline and advance its lead therapeutic compounds in the direction of medical growth.
Led by CEO Zeno Albisser, Hemispherian is a pharmaceutical firm targeted on creating a novel class of small molecule medicine known as GLIX. GLIX compounds goal the TET2 enzyme and activate the DNA harm response leading to most cancers cell loss of life. The corporate’s lead compound, GLIX1, is in late-stage preclinical growth for the remedy of glioblastoma multiforme, a lethal most cancers of the central nervous system and the main explanation for loss of life by illness in youngsters. Hemispherian is additional targeted on creating a companion diagnostic software to assist affected person choice for optimum therapeutic response to GLIX1.